Is Crizotinib a targeted drug in capsule form?

Crizotinib is indeed an oral targeted drug in capsule form and is commonly used to treat patients with non-small cell lung cancer (NSCLC) with specific gene fusion mutations (such as ALK or ROS1 rearrangements). It is a small molecule tyrosine kinase inhibitor that can effectively inhibit targets such as ALK (anaplastic lymphoma kinase), ROS1 and MET, thereby blocking the proliferation signals of tumor cells and inhibiting tumor growth.

Crizotinib is taken orally in the form of capsules, and the common specifications per capsule are 250mg or 200mg. The standard recommended dose is 250 mg twice daily. The specific usage needs to be determined based on the doctor's evaluation and the patient's individual condition. Since it is in capsule form, patients should swallow it whole when taking it, and do not open, crush or chew it to ensure normal release and absorption of the drug in the body.

As a targeted therapy drug, crizotinib has more controllable side effects than traditional chemotherapy, but it also has common adverse reactions, such as visual abnormalities, nausea, diarrhea, fatigue, abnormal liver function, etc. During medication, liver and kidney function, electrolyte levels, electrocardiogram and other indicators need to be closely monitored. Some patients may need to adjust the dose or switch to other targeted drugs due to drug resistance or side effects.

In summary, crizotinib is a targeted therapy drug in the form of oral capsules that is suitable for lung cancer patients with specific genetic mutations. Its convenient taking method provides better compliance for long-term treatment, but it still needs to be used rationally under the guidance of a professional doctor and reviewed regularly to achieve the best treatment effect and reduce risks.

Reference materials:https://go.drugbank.com/drugs/DB08865